Migraine Patients Exhibit Increased Risk Of Developing Chronic Migraine With Sustained Triptan Treatment - Results From A Large-Scale Real-World Claims Analysis

被引：0
|
作者：
Mohajer, Ali [1 ]
L'Italien, Gilbert [2 ]
Harris, Linda [2 ]
Keller, Kathryn [2 ]
Dandona, Harsh [1 ]
Buse, Dawn
Lipton, Richard [3 ]
机构：
[1] QRAL Grp, New York, NY USA
[2] Biohaven Pharmaceut, New Haven, CT USA
[3] Albert Einstein Coll Med, Bronx, NY 10467 USA
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
2391
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Real-world treatment utilisation and safety of onabotulinumtoxinA for chronic migraine: results from an observational study in the European Union
    Matharu, M.
    Pascual, J.
    Nilsson-Remahl, I.
    Straube, A.
    Lum, A.
    Davar, G.
    Odom, D.
    Bennett, L.
    Proctor, C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 : 115 - 115
  • [22] Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or CGRP mAbs: A retrospective claims analysis study
    Schwedt, T. J.
    Lee, J.
    Knievel, K.
    McVige, J. W.
    Wang, W.
    Wu, Z.
    Gillard, P.
    Shah, D.
    Blumenfeld, A. M.
    HEADACHE, 2022, 62 : 81 - 82
  • [23] Real-World Persistence and Costs Among Patients With Chronic Migraine Treated With OnabotulinumtoxinA or CGRP mAbs: A Retrospective Claims Analysis Study
    Schwedt, Todd J.
    Lee, Jae
    Knievel, Kerry
    McVige, Jennifer
    Wang, Weiying
    Wu, Zheng
    Gillard, Patrick
    Shah, Darshini
    Blumenfeld, Andrew M.
    CEPHALALGIA, 2022, 42 (1_SUPPL) : 18 - 19
  • [24] Real-World Persistence and Costs Among Patients With Chronic Migraine Treated With OnabotulinumtoxinA or CGRP mAbs: A Retrospective Claims Analysis Study
    Schwedt, T.
    Lee, J.
    Knievel, K.
    McVige, J.
    Wang, W.
    Wu, Z.
    Gillard, P.
    Shah, D.
    Blumenfeld, A.
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (SUPPL 1):
  • [25] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
    Driessen, Maurice T.
    Cohen, Joshua M.
    Thompson, Stephen F.
    Patterson-Lomba, Oscar
    Seminerio, Michael J.
    Carr, Karen
    Totev, Todor, I
    Sun, Rochelle
    Yim, Erica
    Mu, Fan
    Ayyagari, Rajeev
    JOURNAL OF HEADACHE AND PAIN, 2022, 23 (01):
  • [26] Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine
    Maurice T. Driessen
    Joshua M. Cohen
    Stephen F. Thompson
    Oscar Patterson-Lomba
    Michael J. Seminerio
    Karen Carr
    Todor I. Totev
    Rochelle Sun
    Erica Yim
    Fan Mu
    Rajeev Ayyagari
    The Journal of Headache and Pain, 2022, 23
  • [27] Sustained Benefits of OnabotulinumtoxinA Treatment in Chronic Migraine: Results from a PREEMPT Pooled Analysis
    Silberstein, S.
    Diener, H. -C.
    Dodick, D.
    Luo, L.
    Yedigarova, L.
    Lipton, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 444 - 444
  • [28] Sustained Benefits of OnabotulinumtoxinA Treatment in Chronic Migraine: Results from a PREEMPT Pooled Analysis
    Silberstein, Stephen
    Diener, Hans-Christoph
    Dodick, David
    Yedigarova, Larisa
    Lipton, Richard
    NEUROLOGY, 2020, 94 (15)
  • [29] Sustained Benefits of OnabotulinumtoxinA Treatment in Chronic Migraine: Results From a PREEMPT Pooled Analysis
    Silberstein, S. D.
    Diener, H.
    Dodick, D. W.
    Luo, L.
    Yedigarova, L.
    Lipton, R. B.
    HEADACHE, 2020, 60 : 125 - 125
  • [30] Real-world evidence for chronic migraine control in patients receiving treatment with CGRP mAbs and onabotulinumtoxinA
    Blumenfeld, A.
    Frishberg, B.
    Schim, J.
    Hughes, O.
    Sommer, K.
    Adams, A. Manack
    EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 : 152 - 153
12345